The Role of Biologic Therapy Switching to Optimize the Treatment of Severe Pediatric Asthma: Tezepelumab Is a New Therapeutic Alternative for Adolescents

This case highlights the need to go beyond the traditional criteria, such as lack of efficacy and adverse reactions, when evaluating a switch in biologic therapy for pediatric asthma. Factors such as comorbidities, injection frequency and number, route of administration, and cost should also be considered, as they can directly influence adherence and the clinical outcomes in children and adolescents. As the therapeutic options expand, regular reassessment and personalized adjustments remain essential.